Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after hematopoietic stem cell or solid organ transplantation. The majority of PTLD is of B-cell origin and associated with Epstein-Barr virus (EBV). During the past decade progress has been made in better understanding the pathogenesis of PTLD, and early detection strategies, such as serial measurement of EBV-DNA load in peripheral blood samples, have assisted in the identification of high-risk patients. In addition, novel immunotherapies have been developed, including the use of monoclonal antibodies and adoptive transfer of EBV-specific T cells. Despite these advances, it remains a major challenge to define indications for preemptive therapies for PTLD and to integrate novel therapeutic approaches with conventional therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 29-44 |
Number of pages | 16 |
Journal | Annual Review of Medicine |
Volume | 56 |
DOIs | |
State | Published - 2005 |
Keywords
- Epstein-Barr virus
- Hematopoietic stem cell transplant
- Immunotherapy
- Lymphoma
- Solid organ transplant
ASJC Scopus subject areas
- Cell Biology
- Medicine(all)